NEW YORK (GenomeWeb News) — MDS today yesterday reported that third-quarter revenue for the segment comprising its MDS Sciex and Molecular Devices units increased 92 percent as organic receipts rose 11 percent and R&D spending doubled.
 
Total revenue for the three months ended July 31 increased to $127 million from $66 million for its MDS Analytical Technologies segment, which includes Sciex and Molecular Devices.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.